Skip to content

Author

Xing-Bing Wang

We have 3 of 155 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Efficacy and Safety of CAR‐T Cell Therapy in Relapsed/Refractory B‐Cell Acute Lymphoblastic Leukemia With Central Nervous System Involvement

In conclusion, CAR‐T therapy offers similar efficacy and safety in R/R B‐ALL patients regardless of CNS involvement, and consolidative allo‐HSCT as consolidation post‐CAR‐T as an independent protective factor for improved EFS and OS in CNSL patients.

Yang-Hong Yu, Hui Xu, Lei Xue et al. · 0 citations
Open access Jul 2026

Ultralow-Dose Interleukin 10-Expressing Chimeric Antigen Receptor T Cells in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Nonrandomized Clinical Trial.

The results of this nonrandomized clinical trial suggest that ultralow-dose META 10-19 demonstrated promising antitumor activity and a manageable safety profile in patients with R/R DLBCL.

Yong-Xian Hu, Ming-Ming Zhang, M. Gao et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.